Italia markets open in 8 hours 28 minutes

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
6,35+0,24 (+3,93%)
Alla chiusura: 04:00PM EST
6,30 -0,05 (-0,79%)
Dopo ore: 05:42PM EST

bluebird bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
339 499 9300
https://www.bluebirdbio.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno518

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Andrew ObenshainPres, CEO & Director842,85kN/D1975
Mr. Thomas J. KlimaChief Commercial Officer & COO509,7kN/D1972
Mr. Christopher Krawtschuk CPACFO, Principal Accounting Officer & TreasurerN/DN/D1974
Mr. Joseph D. Vittiglio Esq., J.D.Chief Bus. & Legal OfficerN/DN/D1972
Jess RowlandsHead of Corp. CommunicationsN/DN/DN/D
Ms. Andrea WaltonChief People OfficerN/DN/DN/D
Ms. Melissa BonnerSr. VP of ResearchN/DN/DN/D
Mr. Richard Colvin M.D., Ph.D.Chief Medical OfficerN/DN/DN/D
Mr. Kasra KasraianSr. VP of Technical Devel. & OperationsN/DN/DN/D
Mr. Scott ShoemakerSr. VP of QualityN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di bluebird bio, Inc. al 28 gennaio 2023 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 5; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.